By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
Currency | US Dollars |
Share Price | $ 144.87 |
Change Today | $ 1.19 |
% Change | 0.83 % |
52 Week High | $146.68 |
52 Week Low | $143.39 |
Volume | 1,502,045 |
Shares Issued | 145.80m |
Market Cap | $21,122m |
RiskGrade | 259 |
Strong Buy | 7 |
Buy | 5 |
Neutral | 21 |
Sell | 0 |
Strong Sell | 0 |
Total | 33 |
Time | Volume / Share Price |
16:00 | 114 @ $144.87 |
16:00 | 236,373 @ $144.87 |
15:59 | 1,684 @ $144.87 |
15:59 | 100 @ $144.87 |
15:59 | 100 @ $144.87 |
You are here: research